Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10906346 | 0.85 | CYP3A4 (0.48) | CYP3A4TSHRLPAR3LPAR1 | |
| SCHEMBL32660821 | 0.85 | LMNA (0.44) | — | |
| SCHEMBL25353671 | 0.83 | CYP3A4 (0.60) | CYP3A4ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL28676569 | 0.83 | LPAR3 (0.47) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28654693 | 0.81 | LPAR3 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL32660802 | 0.81 | HPGD (0.42) | — | |
| SCHEMBL28673133 | 0.81 | LPAR3 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL11383675 | 0.81 | LPAR3 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3671797 | 0.81 | LPAR3 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28654607 | 0.81 | LPAR3 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | CYP3A4 1005/4885ALDH1A1 4365/4885TSHR 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.